Retatrutide, 5mg

$149.95

897 in stock

Free shipping on all orders over $100 (US) and $300 (International)

• 7-Days Return Policy

Guaranteed Safe Checkout:

Retatrutide, 5mg 1

Description

Retatrutide (LY-3437943) is a promising anti-obesity agent. It is designed to be a triple hormone receptor agonist, meaning it activates three important receptors in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). These receptors play crucial roles in regulating glucose levels and metabolic functions in the body.

Description

Retatrutide (LY-3437943) is a promising anti-obesity agent. It is designed to be a triple hormone receptor agonist, meaning it activates three important receptors in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). These receptors play crucial roles in regulating glucose levels and metabolic functions in the body.

Properties

  • Chemical Formula :C221H342N46O68
  • Molar Mass :4731.33 g/mol
  • CAS Number :2381089-83-2
  • Total Amount of the Active Ingredient :5 mg (1 vial)
  • Shelf Life :36 months

Retatrutide (LY-3437943) is a promising anti-obesity agent. It is designed to be a triple hormone receptor agonist, meaning it activates three important receptors in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). These receptors play crucial roles in regulating glucose levels and metabolic functions in the body.

  • Chemical Formula :C221H342N46O68
  • Molar Mass :4731.33 g/mol
  • CAS Number :2381089-83-2
  • Total Amount of the Active Ingredient :5 mg (1 vial)
  • Shelf Life :36 months
Retatrutide

Product Quality Guaranteed

All of our products are lab tested and the results are occasionally published on the website.

You can have the product you bought from us tested at any HPLC-licensed testing facility and if the results are negative, we will refund the following:

  • Cost of HPLC test
  • Total amount of the order + shipping fee

Peer-Reviewed Studies

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Ania M Jastreboff, Lee M Kaplan, Juan P Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L Hartman

Retatrutide Phase 2 Obesity Trial Investigators, Clinical Trial, N Engl J Med, 389(6):514-526. doi: 10.1056/NEJMoa2301972

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Julio Rosenstock, Juan Frias, Ania M Jastreboff, Yu Du, Jitong Lou, Sirel Gurbuz, Melissa K Thomas, Mark L Hartman, Axel Haupt, Zvonko Milicevic, Tamer Coskun.

Clinical Trial, Lancet, 402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X.

Other Products Explore All

Explore All